Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

Campone, M; Levy, V; Bourbouloux, E; Berton Rigaud, D; Bootle, D; Dutreix, C; Zoellner, U; Shand, N; Calvo, F; Raymond, E

Campone, M; Levy, V; Bourbouloux, E; Berton Rigaud, D; Bootle, D; Dutreix, C; Zoellner, U; Shand, N; Calvo, F; Raymond, E.

Affiliation

Campone M; Department of Medical Oncology, Centre René Gauducheau, Nantes, France.

Br J Cancer ; 100(2): 315-21, 2009 Jan 27.

Article in En | MEDLINE | ID: mdl-19127256

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics; Neoplasms/metabolism; Protein Kinases/chemistry; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Dose-Response Relationship, Drug; Drug Monitoring; Everolimus; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms/drug therapy; Neoplasms/pathology; Paclitaxel/administration & dosage; Prognosis; Protein Kinases/metabolism; Sirolimus/administration & dosage; Sirolimus/analogs & derivatives; Survival Rate; TOR Serine-Threonine Kinases; Tissue Distribution; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Kinases / Antineoplastic Combined Chemotherapy Protocols / Neoplasms Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2009 Document type: Article Affiliation country: France Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google